Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.55
-4.4%
$0.65
$0.48
$2.48
$15.65M1.03325,850 shs173,649 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.09
-3.3%
$0.10
$0.02
$0.15
$14.28M2.59195,713 shs49,365 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$2.42
-0.4%
$2.60
$2.33
$4.96
$15.25M0.3833,338 shs5,953 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$6.10
+4.0%
$6.95
$2.98
$80.10
$3.32M2.742.33 million shs13,835 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
+1.79%+5.56%-18.70%-17.89%-55.81%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
+4.55%+8.24%-8.09%+102.20%+217.24%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-2.02%-3.19%-4.71%-10.99%-28.53%
SciSparc Ltd. stock logo
SPRC
SciSparc
-15.32%-27.11%+37.24%+47.79%-90.23%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.55
-4.4%
$0.65
$0.48
$2.48
$15.65M1.03325,850 shs173,649 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.09
-3.3%
$0.10
$0.02
$0.15
$14.28M2.59195,713 shs49,365 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$2.42
-0.4%
$2.60
$2.33
$4.96
$15.25M0.3833,338 shs5,953 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$6.10
+4.0%
$6.95
$2.98
$80.10
$3.32M2.742.33 million shs13,835 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
+1.79%+5.56%-18.70%-17.89%-55.81%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
+4.55%+8.24%-8.09%+102.20%+217.24%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-2.02%-3.19%-4.71%-10.99%-28.53%
SciSparc Ltd. stock logo
SPRC
SciSparc
-15.32%-27.11%+37.24%+47.79%-90.23%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.25
Hold$5.00817.26% Upside
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.00
SellN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SPRC, NAII, CTXR, and GRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
Reiterated RatingSell (E+)
5/26/2026
SciSparc Ltd. stock logo
SPRC
SciSparc
Reiterated RatingSell (E+)
5/19/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
UpgradeHold
5/18/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Reiterated RatingBuy$4.00
3/27/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Reiterated RatingSell (E+)
(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/A$4.29 per shareN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$129.86M0.12N/AN/A$11.07 per share0.22
SciSparc Ltd. stock logo
SPRC
SciSparc
$860K4.04N/AN/A$12.93 per share0.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$37.43M-$2.13N/AN/AN/AN/A-61.09%-35.36%8/11/2026 (Estimated)
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M$0.64N/AN/AN/AN/AN/A-99.34%8/12/2026 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$13.57M-$2.39N/AN/AN/A-10.13%-12.21%-5.30%N/A
SciSparc Ltd. stock logo
SPRC
SciSparc
-$12.18MN/AN/AN/AN/AN/AN/AN/AN/A

Latest SPRC, NAII, CTXR, and GRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/18/2026Q3 2026
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.72N/A-$0.72N/A$35.48 million
5/15/2026Q2 2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$0.2808-$0.95-$0.6693-$0.95$10.23 millionN/A
4/29/2026Q4 2025
SciSparc Ltd. stock logo
SPRC
SciSparc
N/A-$31.6050N/A-$31.6050N/A$0.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/A
0.58
0.16
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
9.74
9.74
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.13
1.64
0.87
SciSparc Ltd. stock logo
SPRC
SciSparc
N/A
2.41
2.38

Institutional Ownership

CompanyInstitutional Ownership
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
16.88%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
50.77%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
SciSparc Ltd. stock logo
SPRC
SciSparc
25.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2027.45 million26.08 millionOptionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
30160.43 million47.38 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.28 million4.97 millionNot Optionable
SciSparc Ltd. stock logo
SPRC
SciSparc
4570,000557,000Not Optionable

Recent News About These Companies

Neurothera Labs Announces Continuance into Ontario

New MarketBeat Followers Over Time

Media Sentiment Over Time

Citius Pharmaceuticals stock logo

Citius Pharmaceuticals NASDAQ:CTXR

$0.55 -0.02 (-4.37%)
Closing price 04:00 PM Eastern
Extended Trading
$0.55 +0.01 (+1.08%)
As of 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Galera Therapeutics stock logo

Galera Therapeutics NASDAQ:GRTX

$0.09 0.00 (-3.26%)
As of 03:37 PM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$2.42 -0.01 (-0.41%)
Closing price 04:00 PM Eastern
Extended Trading
$2.43 +0.01 (+0.25%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

SciSparc stock logo

SciSparc NASDAQ:SPRC

$6.10 +0.24 (+4.01%)
Closing price 03:58 PM Eastern
Extended Trading
$6.10 0.00 (0.00%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.